Newborn screening for cystic fibrosis
Tanja Gonska1,2, Felix Ratjen2,3
1a 1 Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, University of Toronto, Toronto, ON, Canada.
Insights
Newborn screening for cystic fibrosis (CF NBS) identifies most children before symptoms appear. This review examines CF NBS benefits, screening methods, and challenges like inconclusive test results.
Area of Science:
- Medical Genetics
- Pediatric Pulmonology
- Public Health Screening
Background:
- Newborn screening for cystic fibrosis (CF NBS) is widely implemented in Western countries.
- Early identification of cystic fibrosis (CF) is crucial for timely intervention and improved outcomes.
- CF NBS aims to detect the disease before clinical symptoms manifest.
Purpose of the Study:
- To review the evidence supporting the benefits of CF NBS.
- To describe various screening algorithms used globally.
- To address challenges associated with false-negative and false-positive screening results, and inconclusive diagnoses.
Main Methods:
- Literature review of existing evidence on CF NBS.
- Analysis of different jurisdictional screening algorithms.
- Examination of data on outcomes for screened newborns, particularly those with inconclusive sweat tests.
Main Results:
- CF NBS has become a standard practice, identifying most CF cases presymptomatically.
- Diverse screening algorithms are employed, each with unique advantages and limitations.
- False-negative and false-positive results pose significant challenges in CF NBS implementation.
- A subset of newborns screened positive for CF receive inconclusive results from confirmatory sweat testing.
Conclusions:
- CF NBS is effective in early detection of cystic fibrosis.
- Standardization of screening algorithms and clear protocols for managing inconclusive results are needed.
- Further research is required to optimize CF NBS protocols and address diagnostic uncertainties.
Abstract:
Newborn screening for cystic fibrosis (CF NBS) has been introduced in almost all of the Western countries, and most of the children with CF are now being identified via CF NBS before disease-related symptoms develop. This review summarizes the evidence that has been generated to date to support the benefit of CF NBS and the various screening algorithms that are used in different jurisdictions. A special focus is directed towards the challenges arising from false-negative and -positive screening results. Finally, we review the emerging data reporting on positively-screened newborns, in whom confirmatory sweat testing resulted in an inconclusive diagnosis for CF.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...


